Gwendolyn Yamada demandée il y a 4 heures
Hyzaar is a fixed-dose combination medication containing losartan potassium, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide (HCTZ), a thiazide diuretic. Approved by the U.S. Food and Drug Administration (FDA) in 1995, it is primarily indicated for the treatment of hypertension to lower blood pressure and reduce the risk of stroke and cardiovascular events. This report provides a concise summary of its pharmacology, clinical uses, efficacy, safety, and practical considerations.
Pharmacology and Mechanism of Action
Losartan selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of the renin-angiotensin-aldosterone system (RAAS). This leads to vasodilation, reduced peripheral resistance, and decreased sodium and water retention. Hydrochlorothiazide acts on the distal convoluted tubule of the nephron, inhibiting the sodium-chloride cotransporter, which increases excretion of sodium, chloride, and water, resulting in reduced plasma volume and lowered blood pressure. The combination provides synergistic antihypertensive effects, often achieving greater blood pressure reduction than either agent alone, while also counterbalancing some of the electrolyte disturbances (e.g., hypokalemia) caused by HCTZ alone.
Indications and Dosage
Hyzaar is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled on monotherapy. It is also used as initial therapy in patients likely to need multiple drugs to achieve target blood pressure. The available strengths are 50 mg losartan / 12.5 mg HCTZ and 100 mg / 25 mg. The usual starting dose is 50/12.5 mg once daily, titrated as needed up to 100/25 mg daily. It is important to correct any volume or sodium depletion prior to initiation to minimize the risk of symptomatic hypotension.
Clinical Efficacy
Numerous randomized controlled trials have demonstrated the superiority of Hyzaar over placebo and monotherapy components in reducing both systolic and diastolic blood pressure. In the Losartan Intervention For Endpoint Reduction (LIFE) study, losartan-based therapy (with HCTZ added as needed) significantly reduced the risk of cardiovascular morbidity and – https://mutuelle-geodis.com – mortality compared to atenolol-based therapy in hypertensive patients with left ventricular hypertrophy. The combination also showed favorable effects on stroke prevention and regression of left ventricular mass. Ambulatory blood pressure monitoring studies confirm sustained 24-hour efficacy.
Safety and Adverse Effects
Hyzaar is generally well-tolerated. Common adverse effects include dizziness, fatigue, and upper respiratory infection. HCTZ may cause electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, and increased blood glucose and lipid levels. Losartan may rarely cause angioedema, renal impairment, or hyperkalemia. The combination product may also cause orthostatic hypotension, especially in volume-depleted patients. Caution is advised in patients with severe renal impairment, bilateral renal artery stenosis, or history of hypersensitivity to sulfonamides (HCTZ is a sulfonamide derivative). Regular monitoring of renal function, serum electrolytes, and blood glucose is recommended.
Contraindications and Drug Interactions
Contraindications include anuria, hypersensitivity to any component, and pregnancy (due to risk of fetal toxicity from ARBs). Concomitant use with aliskiren is contraindicated in patients with diabetes or moderate-to-severe renal impairment. Drug interactions include NSAIDs (reduced antihypertensive effect, increased renal risk), lithium (increased toxicity), non-depolarizing muscle relaxants, and corticosteroids. Hyperkalemia risk increases with potassium supplements or potassium-sparing diuretics.
Special Populations
In the elderly, starting with the lowest dose and careful titration is advised. Hyzaar is not recommended for breastfeeding mothers due to potential effects on the infant. In patients with mild-to-moderate hepatic impairment, losartan dosing requires caution; the combination may not be optimal. For those with severe hepatic impairment, use is not recommended.
Clinical Pearls
- The combination is particularly useful for patients who do not achieve goal blood pressure on a single agent, especially when an ARB and a low-dose diuretic are appropriate.
- Because HCTZ can cause hypokalemia, the losartan component helps mitigate this effect by reducing aldosterone-mediated potassium loss.
- The fixed-dose combination improves adherence by reducing pill burden.
- Peak effects occur within 3–6 weeks of therapy, so dose adjustments should follow an appropriate interval.
Conclusion
Hyzaar is a well-established, evidence-based combination antihypertensive that leverages complementary mechanisms to achieve robust blood pressure reduction with a favorable safety profile when used appropriately. It remains a valuable option in the management of hypertension, especially in patients with comorbid conditions such as left ventricular hypertrophy. Clinicians should consider patient-specific factors, monitor for electrolyte and renal changes, and adhere to prescribing guidelines to optimize outcomes.